Clinical trial
A Phase I, Prospective, Open-Labeled Study to Evaluate the Safety and Immunogenicity of MVC-COV1901
NCT04487210 is registered in ClinicalTrials.gov with Medigen Vaccine Biologics Corp. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Prospective, Open-Labeled Study to Evaluate the Safety and Immunogenicity of MVC-COV1901
- Lead sponsor
- Medigen Vaccine Biologics Corp.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 7, 2020
- Completion date
- December 6, 2021
- Enrollment
- 45 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.